In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

about

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Item

http://www.wikidata.org/entity/Q35822578

description

1994 nî lūn-bûn

@nan

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

1994年论文

@zh

1994年论文

@zh-cn

name

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

@ast

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

@en

type

Item

label

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

@ast

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

@en

prefLabel

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

@ast

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

@en

P1476

In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

@en

P2093

Bisignano G

http://www.w3.org/2001/XMLSchema#string

Cerniglia G

http://www.w3.org/2001/XMLSchema#string

Cesana M

http://www.w3.org/2001/XMLSchema#string

Furneri PM

http://www.w3.org/2001/XMLSchema#string

Nicoletti G

http://www.w3.org/2001/XMLSchema#string

Tempera G

http://www.w3.org/2001/XMLSchema#string

P2860

Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis

The in-vitro activity of two new quinolones: rufloxacin and MF 961

In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone

In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

The penetration of rufloxacin into sites of potential infection in the respiratory tract.

Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.

Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function

In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.

P304

2651-2654

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.38.11.2651

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

1994-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15325990

http://www.w3.org/2001/XMLSchema#string

P698

7872762

http://www.w3.org/2001/XMLSchema#string

P932

188257

http://www.w3.org/2001/XMLSchema#string